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Drug discovery accumulates experimental data very fast. Nowadays, more than 100 million 
of compounds available in PubChem and other databases which contain information about biological 
activities and other pharmaceutically important properties of compounds. However, the size of 
chemical space of drug-like molecules is much larger and is estimated to ~10
36
 compounds. 
Utilization of accumulated knowledge to navigate in such a vast space is invaluable for drug 
discovery. This can greatly speed up a whole discovery process and reduce overall costs for research 
of new therapeutically relevant compounds. 
Nowadays, different ligand- and structure-based in silico approaches proved their utility in 
drug discovery. Most widely used are similarity search, QSAR and pharmacophore modeling, 
molecular docking which represent molecular structure from different perspectives. All these 
methods have their own drawbacks and advantages. Application of a single tool for virtual screening 
can be successful. However, single computational models are not accurate enough to identify hits 
with high successful rates in all cases. Therefore, using different tools in combination is a more 
reasonable strategy. Founding an agreement between different models can decrease the number of 
compounds to be tested and significantly improve hit rates. On the other hand combining a lot of 
different models may reduce the novelty of identified compounds. Nowadays, in silico screening 
became already a routine procedure and a lot of examples of successful applications were published 
recent years. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
